Exchange: NASDAQ·Updated 06:00 PM EDT
CRBP logo

CRBPCorbus Pharmaceuticals Holdings Inc

$9.14
$0.21
(2.39%)
Today
Closed $9.01
$0.13
(1.44%)
After Hours
EarningsAug 11
Mkt Cap$163.04M
Vol215,843.00
News
all
press releases
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio As CMO
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a company focused on oncology and obesity, said on Monday that it has appointed Leonardo Viana Nicacio as Chief Medical Officer...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim
Guggenheim upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...
MarketBeat
News Placeholder
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...
MarketBeat
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating
Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...
MarketBeat
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...
MarketBeat
News Placeholder
Corbus Pharmaceuticals Holdings, Inc. $CRBP Stock Holdings Lifted by Aberdeen Group plc
Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...
MarketBeat
News Placeholder
Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...
Nasdaq News: Markets
News Placeholder
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...
MarketBeat
News Placeholder
HC Wainwright Issues Negative Forecast for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.